$PRTA
PROTHENA CORP PUBLIC LTD CO Stock $prta

$prta Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000155905323000016 Filed on May 04, 2023

Income Statement

Concept	2023 Q2	2023 Q1
Revenue	$4.019M	$2.169M
YoY Change	206.33%	88.12%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$14.51M	$13.74M
YoY Change	12.04%	16.08%
% of Gross Profit
Research & Development	$56.01M	$44.76M
YoY Change	77.42%	64.17%
% of Gross Profit
Depreciation & Amortization	$200.0K	$201.0K
YoY Change	0.0%	10.44%
% of Gross Profit
Operating Expenses	$70.52M	$58.49M
YoY Change	58.4%	49.61%
Operating Profit	-$66.50M	-$56.33M
YoY Change	53.91%	48.44%
Interest Expense	$7.700M	$6.690M
YoY Change	1105.01%	12522.64%
% of Operating Profit
Other Income/Expense, Net	$7.603M	$6.549M
YoY Change	1093.56%	-38623.53%
Pretax Income	-$58.90M	-$49.78M
YoY Change	38.36%	31.12%
Income Tax	-$4.300M	-$2.900M
% Of Pretax Income
Net Earnings	-$54.60M	-$46.86M
YoY Change	32.37%	29.14%
Net Earnings / Revenue	-1358.42%	-2160.63%
Basic Earnings Per Share	-$1.03	-$0.89
Diluted Earnings Per Share	-$1.03	-$0.89
COMMON SHARES
Basic Shares Outstanding	52.75M shares	52.56M shares
Diluted Shares Outstanding	53.12M shares	52.50M shares

Balance Sheet

Concept	2023 Q2	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$659.1M	$686.2M
YoY Change	29.54%	26.37%
Cash & Equivalents	$659.1M	$686.2M
Short-Term Investments
Other Short-Term Assets	$17.47M	$14.16M
YoY Change	39.76%	12.14%
Inventory
Prepaid Expenses
Receivables	$524.0K
Other Receivables	$0.00
Total Short-Term Assets	$677.1M	$700.3M
YoY Change	29.89%	26.05%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.170M	$1.924M
YoY Change	16.6%	3.16%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$11.27M	$10.96M
YoY Change	197.75%	372.4%
Total Long-Term Assets	$43.55M	$41.24M
YoY Change	53.9%	59.91%
TOTAL ASSETS
Total Short-Term Assets	$677.1M	$700.3M
Total Long-Term Assets	$43.55M	$41.24M
Total Assets	$720.6M	$741.6M
YoY Change	31.13%	27.55%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$13.85M	$12.52M
YoY Change	83.43%	34.42%
Accrued Expenses	$30.65M	$24.68M
YoY Change	43.25%	47.58%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$71.57M	$48.88M
YoY Change	78.44%	33.94%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$0.00	$0.00
YoY Change	-100.0%	-100.0%
Total Long-Term Liabilities	$67.41M	$85.29M
YoY Change	-34.04%	-19.56%
TOTAL LIABILITIES
Total Short-Term Liabilities	$71.57M	$48.88M
Total Long-Term Liabilities	$67.41M	$85.29M
Total Liabilities	$139.0M	$134.2M
YoY Change	-2.33%	-5.86%
SHAREHOLDERS EQUITY
Retained Earnings	-$934.5M	-$879.9M
YoY Change	17.75%	16.96%
Common Stock	$535.0K	$527.0K
YoY Change	14.32%	12.85%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$581.7M	$607.4M
YoY Change
Total Liabilities & Shareholders Equity	$720.6M	$741.6M
YoY Change	31.13%	27.55%

Cashflow Statement

Concept	2023 Q2	2023 Q1
OPERATING ACTIVITIES
Net Income	-$54.60M	-$46.86M
YoY Change	32.37%	29.14%
Depreciation, Depletion And Amortization	$200.0K	$201.0K
YoY Change	0.0%	10.44%
Cash From Operating Activities	-$44.93M	-$47.46M
YoY Change	27.41%	26.84%
INVESTING ACTIVITIES
Capital Expenditures	$771.0K	$48.00K
YoY Change	-578.88%	-318.18%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$771.0K	-$48.00K
YoY Change	378.88%	118.18%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	18.63M	$23.28M
YoY Change	1420.41%	1641.51%
NET CHANGE
Cash From Operating Activities	-44.93M	-$47.46M
Cash From Investing Activities	-771.0K	-$48.00K
Cash From Financing Activities	18.63M	$23.28M
Net Change In Cash	-27.07M	-$24.22M
YoY Change	-20.84%	-32.9%
FREE CASH FLOW
Cash From Operating Activities	-$44.93M	-$47.46M
Capital Expenditures	$771.0K	$48.00K
Free Cash Flow	-$45.70M	-$47.51M
YoY Change	30.19%	27.05%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001559053
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2016Q1	prta	Lease Agreement Term Of Contract LeaseAgreementTermOfContract	P7Y9M30D
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-35676
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	PROTHENA CORPORATION PUBLIC LIMITED COMPANY
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	L2
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1111119
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	77 Sir John Rogerson’s Quay, Block C
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Grand Canal Docklands
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Dublin 2,
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	D02 VK60,
CY2023Q1	dei	Entity Address Country EntityAddressCountry	IE
CY2023Q1	dei	Country Region CountryRegion	353
CY2023Q1	dei	City Area Code CityAreaCode	1
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	236-2500
CY2023Q1	dei	Security12b Title Security12bTitle	Ordinary Shares, par value $0.01 per share
CY2023Q1	dei	Trading Symbol TradingSymbol	PRTA
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	52751775	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	686184000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	710406000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	14159000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8692000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	700343000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	719098000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1731000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4719000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	6277000	usd
CY2023Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	21433000	usd
CY2022Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	18204000	usd
CY2023Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2212000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2212000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	10955000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	10513000	usd
CY2023Q1	us-gaap	Assets Noncurrent AssetsNoncurrent	41243000	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	38937000	usd
CY2023Q1	us-gaap	Assets Assets	741586000	usd
CY2022Q4	us-gaap	Assets Assets	758035000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	12523000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	9270000	usd
CY2023Q1	prta	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	14156000	usd
CY2022Q4	prta	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	10794000	usd
CY2023Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	9323000	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	11442000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4885000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	6473000	usd
CY2023Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	7997000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	12168000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	48884000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	50147000	usd
CY2023Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	85293000	usd
CY2022Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	85293000	usd
CY2023Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	553000	usd
CY2023Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	85293000	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	85846000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	134177000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	135993000	usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	prta	Deferred Shares Par Value DeferredSharesParValue	22
CY2023Q1	prta	Deferred Shares Par Value DeferredSharesParValue	22
CY2023Q1	prta	Deferred Shares Value DeferredSharesValue	0	usd
CY2022Q4	prta	Deferred Shares Value DeferredSharesValue	0	usd
CY2022Q4	prta	Deferred Shares Shares Authorized DeferredSharesSharesAuthorized	10000	shares
CY2023Q1	prta	Deferred Shares Shares Authorized DeferredSharesSharesAuthorized	10000	shares
CY2023Q1	prta	Deferred Shares Share Issued DeferredSharesShareIssued	0	shares
CY2022Q4	prta	Deferred Shares Share Issued DeferredSharesShareIssued	0	shares
CY2022Q4	prta	Deferred Shares Share Outstanding DeferredSharesShareOutstanding	0	shares
CY2023Q1	prta	Deferred Shares Share Outstanding DeferredSharesShareOutstanding	0	shares
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	527000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	521000	usd
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	52678178	shares
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13738000	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11835000	usd
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	52678178	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	52103608	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	52103608	shares
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1486749000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1454524000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-879867000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-833003000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	607409000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	622042000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	741586000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	758035000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2169000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1153000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	44756000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	27262000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	58494000	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	39097000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-56325000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-37944000	usd
CY2023Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	6690000	usd
CY2022Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	53000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-141000	usd
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-70000	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	6549000	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-17000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-49776000	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-37961000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2912000	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1671000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-46864000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-36290000	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.89
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.78
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.89
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.78
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	52501000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	46704000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	52501000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	46704000	shares
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-46864000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-36290000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	201000	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	182000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	8790000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	7660000	usd
CY2023Q1	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-3229000	usd
CY2022Q1	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-2521000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1558000	usd
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1459000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	5935000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	7104000	usd
CY2023Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-2119000	usd
CY2022Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-1104000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1728000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1745000	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1588000	usd
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1442000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-47458000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-37415000	usd
CY2023Q1	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	48000	usd
CY2022Q1	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	22000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-48000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-22000	usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2602000	usd
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1488000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	23284000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1337000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-24222000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-36100000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	712618000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	580446000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	688396000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	544346000	usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2022Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	9000	usd
CY2023Q1	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	345000	usd
CY2022Q1	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	13000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	686184000	usd
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	542994000	usd
CY2023Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	0	usd
CY2022Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	0	usd
CY2023Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2212000	usd
CY2022Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1352000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	688396000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	544346000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	622042000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8790000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2540000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-46864000	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	607409000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	466042000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7660000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1475000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-36290000	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	438887000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-879900000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	686200000	usd
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Condensed Consolidated Financial Statements in conformity with GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates, including critical accounting policies or estimates related to revenue recognition, share-based compensation, research and development expenses and leases. The Company bases its estimates on historical experience and on various other market specific and other relevant assumptions that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Because of the uncertainties inherent in such estimates, actual results may differ materially from these estimates.</span></div>
CY2023Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risks and Other Risks and Uncertainties</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents. The Company places its cash equivalents with multiple major and reputable financial institutions. To minimize our risk the Company and its subsidiaries invest pursuant to a Board approved investment policy, which specifies credit quality standards for our investments and limits the amount of credit exposure to any single issue, issuer or type of investment. The majority of cash and cash equivalents are invested in liquid money market funds. Cash deposits held with banks may exceed the amount of insurance provided on such deposits. To date, the Company has not experienced any losses on its deposits of cash and cash equivalents.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s business is primarily conducted in U.S. dollars except for its agreements with contract manufacturers for drug supplies which are denominated in Euros. The Company recorde</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d a loss on</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> foreign currency exchange rate differences of approxim</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ately $141,000 and $70,000 during the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended March 31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2022, respectively. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> If the Company increases its business activities that require the use of foreign currencies, it may be exposed to losses if the Euro and other such currencies continue to strengthen against the U.S. dollar.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and December 31, 2022, approximately </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.9 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.7 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively, of the Company’s property and equipment, net were held in the U.S. and nominal amount were in Ireland.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to a number of risks similar to other late-stage clinical biotechnology companies, including, but not limited to, the need to obtain adequate additional funding, possible failure of current or future preclinical testing or clinical trials, its reliance on third parties to conduct its clinical trials, the need to obtain regulatory and marketing approvals for its drug candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company’s drug candidates, its right to develop and commercialize its drug candidates pursuant to the terms and conditions of the licenses granted to the Company, protection of proprietary technology, and the need to secure and maintain adequate clinical trial management, manufacturing, packaging, labeling, storage, testing, and distribution arrangements with third parties. The Company also relies on third party consultants to assist in managing these third parties and assist with its clinical trial operations and manufacturing. If the Company does not successfully commercialize or partner any of its drug candidates, it will be unable to generate product revenue or achieve profitability. Further, the Company is also subject to broad market risks and uncertainties resulting from recent events, such as the COVID-19 pandemic, the Russian invasion of Ukraine, inflation, rising interest rates, and recession risks, as well as supply chain and labor shortages.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segments</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates in one segment. The Company’s chief operating decision maker (the “CODM”), its Chief Executive Officer, manages the Company’s operations on a consolidated basis for purposes of allocating resources. When evaluating the Company’s financial performance, the CODM reviews all financial information on a consolidated basis.</span></div>
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Before Reclassification And Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax	141000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Before Reclassification And Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax	70000	usd
CY2023Q1	prta	Prepaid Research And Development Expenses PrepaidResearchAndDevelopmentExpenses	6828000	usd
CY2022Q4	prta	Prepaid Research And Development Expenses PrepaidResearchAndDevelopmentExpenses	5325000	usd
CY2023Q1	prta	Prepaid General And Administrative Expense PrepaidGeneralAndAdministrativeExpense	4061000	usd
CY2022Q4	prta	Prepaid General And Administrative Expense PrepaidGeneralAndAdministrativeExpense	1597000	usd
CY2023Q1	prta	Receivable From Stock Option Exercises In Transit ReceivableFromStockOptionExercisesInTransit	0	usd
CY2022Q4	prta	Receivable From Stock Option Exercises In Transit ReceivableFromStockOptionExercisesInTransit	62000	usd
CY2023Q1	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	3270000	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	1708000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	14159000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8692000	usd
CY2023Q1	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	10179000	usd
CY2022Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	9901000	usd
CY2023Q1	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	1498000	usd
CY2022Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	1498000	usd
CY2023Q1	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	1615000	usd
CY2022Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	1500000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	13292000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	12899000	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	11368000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	11168000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1924000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1731000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	200000	usd
CY2022Q1	us-gaap	Depreciation Depreciation	200000	usd
CY2023Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5638000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	11060000	usd
CY2023Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	534000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	605000	usd
CY2023Q1	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	1825000	usd
CY2022Q4	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	503000	usd
CY2023Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	7997000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	12168000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-46864000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-36290000	usd
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	52501000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	46704000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	52501000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	46704000	shares
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.89
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.78
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.89
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.78
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10494000	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10319000	shares
CY2016Q1	prta	Operating Lease Area OperatingLeaseArea	128751	sqft
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y9M
CY2016Q1	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2023-12-31
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	1600000	usd
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	1600000	usd
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	1600000	usd
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	1600000	usd
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0425
CY2018Q3	prta	Operating Leases Sublease Rentals Areaof Sublease Rental OperatingLeasesSubleaseRentalsAreaofSubleaseRental	46641	sqft
CY2023Q1	us-gaap	Sublease Income SubleaseIncome	700000	usd
CY2022Q1	us-gaap	Sublease Income SubleaseIncome	700000	usd
CY2018Q3	prta	Subleaserentals Annual Base Rent Initial Amount SubleaserentalsAnnualBaseRentInitialAmount	2700000	usd
CY2018Q3	prta	Operating Leases Sublease Rentals Percent Annual Rent Increase OperatingLeasesSubleaseRentalsPercentAnnualRentIncrease	0.035
CY2018Q3	prta	Operating Leases Sublease Rentals Termof Contract OperatingLeasesSubleaseRentalsTermofContract	P5Y2M12D
CY2018Q3	prta	Operating Leases Sublease Rentals Percentof Rental Gain Attributableto Sublandlord OperatingLeasesSubleaseRentalsPercentofRentalGainAttributabletoSublandlord	0.50
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	4972000	usd
CY2023Q1	us-gaap	Lessor Operating Lease Payments To Be Received Remainder Of Fiscal Year LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear	2239000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2707000	usd
CY2023Q1	us-gaap	Lessor Operating Lease Payments To Be Received Next Twelve Months LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths	0	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	3051000	usd
CY2023Q1	us-gaap	Lessor Operating Lease Payments To Be Received Two Years LessorOperatingLeasePaymentsToBeReceivedTwoYears	0	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	3158000	usd
CY2023Q1	us-gaap	Lessor Operating Lease Payments To Be Received Three Years LessorOperatingLeasePaymentsToBeReceivedThreeYears	0	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	3269000	usd
CY2023Q1	us-gaap	Lessor Operating Lease Payments To Be Received Four Years LessorOperatingLeasePaymentsToBeReceivedFourYears	0	usd
CY2023Q1	prta	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	2523000	usd
CY2023Q1	prta	Lessor Operating Lease Payment To Be Received After Year Four LessorOperatingLeasePaymentToBeReceivedAfterYearFour	0	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	19680000	usd
CY2023Q1	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	2239000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	87000	usd
CY2023Q1	prta	Lessee Operating Lease Liability Lease Not Yet Commenced LesseeOperatingLeaseLiabilityLeaseNotYetCommenced	14708000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	4885000	usd
CY2023Q1	us-gaap	Purchase Obligation PurchaseObligation	15700000	usd
CY2023Q1	us-gaap	Contractual Obligation ContractualObligation	400000	usd
CY2023Q1	us-gaap	Purchase Obligation PurchaseObligation	15746000	usd
CY2023Q1	us-gaap	Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear	15661000	usd
CY2023Q1	us-gaap	Purchase Obligation Due In Next Twelve Months PurchaseObligationDueInNextTwelveMonths	85000	usd
CY2023Q1	us-gaap	Purchase Obligation Due In Second Year PurchaseObligationDueInSecondYear	0	usd
CY2023Q1	us-gaap	Purchase Obligation Due In Third Year PurchaseObligationDueInThirdYear	0	usd
CY2023Q1	us-gaap	Purchase Obligation Due In Fourth Year PurchaseObligationDueInFourthYear	0	usd
CY2023Q1	prta	Purchase Obligation To Be Paid After Year Four PurchaseObligationToBePaidAfterYearFour	0	usd
CY2023Q1	prta	Purchaseand Contractual Obligation Total PurchaseandContractualObligationTotal	16148000	usd
CY2023Q1	prta	Purchaseand Contractual Obligation Remainderof Fiscal Year PurchaseandContractualObligationRemainderofFiscalYear	15725000	usd
CY2023Q1	prta	Purchase And Contractual Obligation Due In Year One PurchaseAndContractualObligationDueInYearOne	149000	usd
CY2023Q1	prta	Purchaseand Contractual Obligation Duein Second Year PurchaseandContractualObligationDueinSecondYear	64000	usd
CY2023Q1	prta	Purchaseand Contractual Obligation Duein Third Year PurchaseandContractualObligationDueinThirdYear	60000	usd
CY2023Q1	prta	Purchaseand Contractual Obligation Duein Fourth Year PurchaseandContractualObligationDueinFourthYear	60000	usd
CY2023Q1	prta	Purchase And Contractual Obligation Due After Fourth Year PurchaseAndContractualObligationDueAfterFourthYear	90000	usd
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	52678178	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	52678178	shares
CY2023Q1	prta	Numberof Votes NumberofVotes	1	vote
CY2023Q1	prta	Deferred Shares Shares Authorized DeferredSharesSharesAuthorized	10000	shares
CY2023Q1	prta	Deferred Shares Par Value DeferredSharesParValue	22
CY2023Q1	prta	Deferred Shares Share Outstanding DeferredSharesShareOutstanding	0	shares
CY2023Q1	prta	Common Stock Cumulative Number Of Shares Issued CommonStockCumulativeNumberOfSharesIssued	911228	shares
CY2023Q1	prta	Proceeds From Issuance Of Common Stock Cumulative Gross Amount ProceedsFromIssuanceOfCommonStockCumulativeGrossAmount	53100000	usd
CY2023Q1	prta	Stock Issuance Costs Cumulative Amount StockIssuanceCostsCumulativeAmount	1700000	usd
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P10Y
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1241171	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1741936	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P4Y
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	1948849	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10470768	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	26.78
CY2023Q1	prta	Share Based Payment Arrangement Estimated Forfeiture Rate ShareBasedPaymentArrangementEstimatedForfeitureRate	0.08
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	8790000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	7660000	usd
CY2023Q1	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	1600000	usd
CY2022Q1	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	1400000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.816
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.821
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.043
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.019
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y10M9D
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	35.37
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	23.14
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9479998	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	23.16
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y9M25D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	354856000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1241171	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	53.13
CY2023Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	179474	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	14.15
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	70927	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	35.98
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	0	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10470768	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	26.78
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y7D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	240912000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	10001226	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	26.10
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P6Y11M1D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	236036000	usd
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	6155015	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	19.68
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y8M19D
CY2023Q1	prta	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value Related To Vested Options ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueRelatedToVestedOptions	179910000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2900000	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1700000	usd

Files In Submission

Name	View Source	Status
prta-20230331_def.xml	Edgar Link	unprocessable
prta-20230331_lab.xml	Edgar Link	unprocessable
prta-20230331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
prta-20230331_cal.xml	Edgar Link	unprocessable
prta-20230331_htm.xml	Edgar Link	completed
0001559053-23-000016-index-headers.html	Edgar Link	pending
0001559053-23-000016-index.html	Edgar Link	pending
0001559053-23-000016.txt	Edgar Link	pending
0001559053-23-000016-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
prta-20230331.htm	Edgar Link	pending
prta-20230331.xsd	Edgar Link	pending
prta2023q110-qxex311.htm	Edgar Link	pending
prta2023q110-qxex312.htm	Edgar Link	pending
prta2023q110-qxex321.htm	Edgar Link	pending
prta2023q1ex101fourteentha.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PRTA
PROTHENA CORP PUBLIC LTD CO Stock $prta

2023 Q2 Form 10-Q Financial Statement

#000155905323000016 Filed on May 04, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PRTA PROTHENA CORP PUBLIC LTD CO Stock $prta

2023 Q2 Form 10-Q Financial Statement

#000155905323000016 Filed on May 04, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PRTA
PROTHENA CORP PUBLIC LTD CO Stock $prta